The field of treatments for multiple sclerosis (MS) has grown quickly in the last 30 years, but the next new class of therapies probably won’t come to market for at least another year and a half, said Daniel Kantor, MD, president of Kantor Neurology.
The field of treatments for multiple sclerosis (MS) has grown quickly in the last 30 years, but the next new class of therapies probably won’t come to market for at least another year and a half, said Daniel Kantor, MD, president of Kantor Neurology.
Transcript
Are there any particular multiple sclerosis trials that you’re keeping an eye on?
The field of MS is exciting. We’ve gone from having zero disease-modifying therapies in 1992, to our first medication in 1993, to, now, having 17 separate products. It’s amazing the leap forward. We now have 14 branded products, we have 2 unbranded generics, and 1 branded generic. That’s an amazing leap forward. That’s faster than anything in neurology, and frankly, faster than most things in medicine.
That means that we’re always looking at the results of new studies that are coming out. Every year for the next several years we’re going to see 1 to 2 new medications coming out. We’ve recently had 2 approvals by the Food and Drug Administration. And we’ll probably se within the next 12 months, we’ll probably see a few more approvals. One of them may be a medication that simply the same medication but just less side effects from one of our common disease-modifying therapies that people take orally twice a day.
Another medication is in a class of medications called S1P, or sphingosine 1-phosphate receptor modulators, and it’s going to be coming out probably within the next 12 to 14 months. Then, we’re going to see other medications that are follow-up medications to other medications that we have, such as, B-cell depleting medications.
We’re not going to see another medication that is a disease-modifying therapy that is from a different class for at least the next year and a half. And that first one might be a BTK inhibitor, or Burton tyrosine kinase inhibitor. And that medication will be an oral medicine. We may or may not see these come to the market. There’s a little bit of a race going on to see who comes out first. And this will be yet another way of treating multiple sclerosis.
The real hope in MS, though, is not just in relapsing forms of MS. It’s really looking at primary progressive forms of multiple sclerosis, as well as a ways of repairing the damage that’s already happened in multiple sclerosis.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Males With Hemophilia A Report Physical, Mental Burdens of Disease Regardless of Severity
April 25th 2024Self-reported data from adult and pediatric males with hemophilia A show that burden of the disease persists regardless of severity, highlighting a need for improved prophylactic treatment.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More